This week, we will discuss the use of 3K dialysis bath with sodium zirconium cyclosilicate versus 2K bath and no potassium lowering medications in dialysis patients and the associated risk of arrhythmia.
This week, we will discuss post-trial follow-up for EMPA-Kidney. What are the longer-term effects of empagliflozin for patients with chronic kidney disease?
Nausea is a very common and distressing problem. Some medications that treat nausea carry a higher risk for arrhythmias, like Torsades de Pointes, and sudden cardiac death. Is ondansetron safe for use in patients on hemodialysis?
This week, we will discuss non-steroidal mineralocorticoid antagonist in the multiverse of cardiovascular-kidney-metabolic. What FINEHEART pooled analysis would add to what we already learned from FIDELIO-DKD trial?
This week is time antibody mediated rejection treatment in kidney transplant. A new molecule targeting CD38, on the horizon, safely tested in a phase 2 trial
This week, we tag along with NephMadness. It will be hard to stay impartial while discussing the role of angiogenic and antiangiogenic factors in severe preeclampsia prognosis.
What do you do when you suspect AIN (and eosinophils aren’t helpful) and you can’t get a kidney biopsy? CXCL9 is a newly discovered urinary marker that may help in the diagnosis of AIN. This week we will discuss the process of isolating and utilizing this new diagnostic test.
Could running marathons be hard on your kidneys, or at least biomarkers that track kidney injury> this paper in AJKD seems to suggest so. Join us to discuss this intriguing data and whether it should impact on runners, on May 23 and 24th.